Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Gene therapy Elevidys expands hope for patients with Duchenne

  Elevidys is a one-time gene therapy that helps patients with DMD produce a key muscle protein and is under ongoing safety evaluation.

• CRISPR gene editing offers new hope for treating Duchenne

  CRISPR shows promise in correcting DMD mutations and restoring dystrophin, and future patients may benefit from personalized strategies.

• Review identifies what physical activity really means to people with DMD

  For people with DMD, physical activity is about more than walking, with independence and quality of life tied to meaningful movement.

• How muscle strength and flexibility shift over time in boys with DMD

  Muscle weakness in Duchenne muscular dystrophy (DMD) does not follow a simple decline, but has periods of stability before worsening.

• Novel gene variants shed light on muscular dystrophy diagnosis

  Researchers identified two previously unreported mutations in the Dystrophin gene, providing new insights into muscular dystrophy.

• Study identified differences in DMD treatment across ethnicities

  Patients of different racial and ethnic backgrounds with DMD received different treatments and had varying health care costs.

• Study: Independence is out of reach for many adults with DMD

  Many individuals with DMD/BMD need assistance with daily living and employment as they transition into adulthood.